

PTO/SB/01 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

Declaration Submitted with Initial

Prior Foreign Application

Number(s)

Declaration Submitted after Initial OR Filing (surcharge (37 ČFR 1.16 (e))

Attorney Docket Num	ıber	EN	P-031		
First Named Inventor		Yat Sun Or			
COMPLETE IF KNOWN					
Application Number			/_		
Filing Date	10	0/12	/0]		
Group Art Unit		TBD			
Examiner Name		TBD			

Filing required) As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: CYCLOSPORIN ANALOGS FOR THE TREATMENT OF LUNG DISEASES (Title of the Invention) the specification of which is attached hereto OR as United States Application Number or PCT International was filed on (MM/DD/YYYY) (if applicable). and was amended on (MM/DD/YYYY) **Application Number** I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the capillaction on which priority is claimed. application on which priority is claimed. **Certified Copy Attached?**

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto: [Page 1 of 2]

Foreign Filing Date

(MM/DD/YYYY)

Country

Priority

Not Claimed

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspo	ondence to: Customer Number or Bar Code L				OR X Co.	rrespondence address below
Sandhya L. Kalkunte (Reg. No. 46,466)						
Enanta Pharmaceuticals, Inc., 500 Arsenal Street						
City	Cambridge			State	MA	ZIP 02472
Country	USA Telephone (617)-			607-0800		(617)-621-9574 Fax
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.						
NAME OF SO	LE OR FIRST INVENTOR :		A petition h	as be	en filed for this un	signed inventor
Given Name Yat Sun Family Name Or or Surname						
Inventor's Signature	lpolar Or				Date 9/28/01	
Residence: City	Cambridge		MA State		Country	USA Citizenship
Mailing Address 225 Walden Street, 2A						
City	Cambridge		MA State	المناوا والمراوع والماء	02140 ZIP	Country USA
NAME OF SE	COND INVENTOR:		A petition ha	s bee	n filed for this uns	igned inventor
Given Name Tsvetelina Ivanova Family Name Lazarova or Surname					a	
Inventor's Signature	Mylles					Date 9 26/0/
Residence: City	Brookline		MA State		USA Country	Bulgaria (BG)
Mailing Addres	20 Dadaway Bood # 2					
City	Brookline		State MA		ZIP 02445	Country
Additional inventors are being named on thesupplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.						

اً. : 1



PTO/SB/81 (02-01)

Approved for use through 10/31/2002. OMB 0651-0035


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number.

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	
Filing Date	
First Named Inventor	Yat Sun Or
Title	Cyclosporin Analogs
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	ENP-031

Practitioners	at Customer Number	一]_		Place Customer Number Bar Code
OR				Label here
X Practitioner(s)	named below:			
	Name		Registrati	ion Number
Sandhya	L. Kalkunte		46,466	
Ronald B.	Goldstein		32,897	
as my/our attorney(s business in the Unite	o) or agent(s) to prosecute the application and States Patent and Trademark Office co	identifi nnecte	ed above, a d therewith	and to transact all
Please change the c	orrespondence address for the above-ide	ntified a	application t	to:
	tioned Customer Number.		_	
OR _				lace Customer lumber Bar Code
	Customer Number			abel here
OR Firm or				
X Individual Name	Sandhya L. Kalkunte			
Address	Enanta Pharmaceuticals, Inc)		
Address	500 Arsenal Street			
City	Watertown	State	MA	Zip 02472
Country	USA			
Telephone	617-607-0800	Fax	617-621	-9574
I am the:				
Applicant/Inv	entor.			
	record of the entire interest. See 37 CFR 3 ander 37 CFR 3.73(b) is enclosed. (Form P		/96).	
	SIGNATURE of Applicant or Assign	nee of	Record	
Name	Spiros Jamas, Sc.D., CEO and Pro			a Pharmaceuticals, Inc.
Signature	S. Jaman.			
Date	9/28/01			
NOTE: Signatures of all the i forms if more than one signa	nventors or assignees of record of the entire interesture is required, see below*.	t or their	representative	e(s) are required. Submit multiple
□ *Total ofTwo	forms are submitted.			

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Applicant/Patent Owner:ENANTA PHARMACEUTICALS, INC.	
· · · · · · · · · · · · · · · · · · ·	
Application No./Patent No.:Filed/Issue Date:	-
Entitled: CYCLOSPORIN ANALOGS FOR THE TREATMENT OF LUNG DISEASES (Atty. Doc ENP-	031)
ENANTA PHARMACEUTICALS, INC. , a CORPORATION	1
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government ag	jency, etc.)
states that it is:	
1. X the assignee of the entire right, title, and interest; or	
an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is%	
in the patent application/patent identified above by virtue of either:	
A. [x] An assignment from the inventor(s) of the patent application/patent identified above. The assignate was recorded in the United States Patent and Trademark Office at Reel, Frame which a copy thereof is attached.	
OR	
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the cur assignee as shown below:	rrent
1. From:To:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
2. From:To:	_
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy thereof is attached.	
3. From:To:To:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
[] Additional documents in the chain of title are listed on a supplemental sheet.	
[x] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
10/1/01 Spiros Jamas, Sc.D.	
Date Typed-or printed name	
S Jaman.	
Signature CEO and President	
Title	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.